~~<i id='665034B091'><strike id='665034B091'><tt id='665034B091'><pre id='665034B091'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

fashion

author：focus 2025-10-01 11:45:41 - browse：79

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

A couple billion here, a couple billion there, and pretty soon Eli Lilly hopes it will be talking about real money.

Eli Lilly agreed to purchase Point Biopharma Tuesday morning for $1.4 billion, a 90% premium, adding to its pipeline of cancer drugs. Point is developing cancer drugs that deliver a focused dose of radiation to tumor cells. Data for its lead medicine, for prostate cancer, are expected in the fourth quarter. It is also developing a drug for neuroendocrine tumors.

Point operates a 180,000-square-foot radiopharmaceutical manufacturing facility in Indianapolis, and a radiopharmaceutical research and development center in Toronto.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： European regulators recommend Amylyx's ALS drug be rejected

hotspot

entertainment

leisure time

knowledge

PauloAmorim/VWPicsviaAPImagesLONDON—Thisweek,EuropeanregulatorsareconsideringanappealfromAmylyxPharm

WSS

How clinical AI models' predictive power can degrade over time

Humana CEO Bruce Broussard to step down in 2024

Spinal cord stimulation reduces pain in amputees, study finds

Patients' immediate access to test results puts radiologists in a bind

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

Kidney disease boosts cardiac arrest risk for Hispanics, Latinos

knowledge

fashion

hotspot

Jerome Adams on the need for new antivirals for Covid

Congenital heart disease patients face new threat of heart failure

Affirmative action in medical school literally saved lives

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

DIEP, the 'gold standard' of breast reconstruction, is under threat

Peter Marks talks Operation Warp Speed for Rare Diseases

Virginia high school admissions case could be legal follow

Supreme Court wrestles with OxyContin maker's bankruptcy deal

State Dept. review finds Biden bears some blame for Afghanistan failures

Medicare to cover more brain scans related to Alzheimer’s drugs

hotspot

European regulators consider appeal over Amylyx ALS drug

What causes an itch? Researchers may have solved the mystery

Congenital heart disease patients face new threat of heart failure

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

What the Wegovy shortage looks like for doctors — and for patients

STAT letters to the editor on burnt

hotspot

entertainment

leisure time

knowledge